These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8485046)

  • 1. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia.
    Potter MN; Steward CG; Oakhill A
    Br J Haematol; 1993 Mar; 83(3):412-8. PubMed ID: 8485046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
    Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
    Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia.
    Goulden N; Langlands K; Steward C; Katz F; Potter M; Chessells J; Oakhill A
    Br J Haematol; 1994 Jun; 87(2):282-5. PubMed ID: 7947268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular detection of acute lymphoblastic leukaemia in boys with testicular relapse.
    Lal A; Kwan E; al Mahr M; Zhou L; Ferrara D; Tobias V; O'Gorman Hughes D; Haber M; Norris MD; Marshall GM
    Mol Pathol; 1998 Oct; 51(5):277-81. PubMed ID: 10193523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in acute lymphoblastic leukaemia--PCR analysis of immunoglobulin gene rearrangements.
    Cole-Sinclair M; Foroni L; Wright F; Mehta A; Prentice HG; Hoffbrand AV
    Leuk Lymphoma; 1993; 11 Suppl 2():49-58. PubMed ID: 8124233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of minimal residual disease in B-cell lineage acute lymphoblastic leukemia of childhood, using clone-specific probes.
    Botsonis T; Tsangaris GT; Mikraki V; Tzortzatou-Stathopoulou F
    Anticancer Res; 1999; 19(3B):2211-20. PubMed ID: 10472333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.
    Brisco MJ; Condon J; Hughes E; Neoh SH; Sykes PJ; Seshadri R; Toogood I; Waters K; Tauro G; Ekert H
    Lancet; 1994 Jan; 343(8891):196-200. PubMed ID: 7904666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse.
    Jacquy C; Delepaut B; Van Daele S; Vaerman JL; Zenebergh A; Brichard B; Vermylen C; Cornu G; Martiat P
    Br J Haematol; 1997 Jul; 98(1):140-6. PubMed ID: 9233577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction.
    Nizet Y; Van Daele S; Lewalle P; Vaerman JL; Philippe M; Vermylen C; Cornu G; Ferrant A; Michaux JL; Martiat P
    Blood; 1993 Sep; 82(5):1618-25. PubMed ID: 8364210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome.
    Nizet Y; Martiat P; Vaerman JL; Philippe M; Wildmann C; Staelens JP; Cornu G; Ferrant A; Michaux JL; Sokal G
    Br J Haematol; 1991 Oct; 79(2):205-10. PubMed ID: 1958477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
    Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
    J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia.
    Wasserman R; Galili N; Ito Y; Silber JH; Reichard BA; Shane S; Womer RB; Lange B; Rovera G
    J Clin Oncol; 1992 Dec; 10(12):1879-88. PubMed ID: 1453203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of minimal residual disease in childhood acute lymphoblastic leukaemia.
    Yeoh AE; Quah TC; Jeyaseelan K; Lee BW; Poh KS; Sun L
    Ann Acad Med Singap; 1997 May; 26(3):365-71. PubMed ID: 9285034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia.
    O'Reilly J; Meyer B; Baker D; Herrmann R; Cannell P; Davies J
    Leukemia; 1995 Apr; 9(4):624-7. PubMed ID: 7723395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
    Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
    Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
    Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
    Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.